Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

All NewsSeptember 10, 2025

PMV Pharma’s Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer achieving a 43% response rate in interim results.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent